These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

755 related articles for article (PubMed ID: 28589214)

  • 21. Treatment of recurrent and severe Clostridium difficile infection.
    Keller JJ; Kuijper EJ
    Annu Rev Med; 2015; 66():373-86. PubMed ID: 25587656
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Treatment of acute and recurrent Clostridium difficile infections : What is new?].
    von Braun A; Lübbert C
    Internist (Berl); 2018 May; 59(5):505-513. PubMed ID: 29536125
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin.
    Tannock GW; Munro K; Taylor C; Lawley B; Young W; Byrne B; Emery J; Louie T
    Microbiology (Reading); 2010 Nov; 156(Pt 11):3354-3359. PubMed ID: 20724385
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative effectiveness of Clostridium difficile treatments: a systematic review.
    Drekonja DM; Butler M; MacDonald R; Bliss D; Filice GA; Rector TS; Wilt TJ
    Ann Intern Med; 2011 Dec; 155(12):839-47. PubMed ID: 22184691
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI.
    Louie TJ; Cannon K; Byrne B; Emery J; Ward L; Eyben M; Krulicki W
    Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S132-42. PubMed ID: 22752862
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Systematic Literature Review of Economic Evaluations of Antibiotic Treatments for Clostridium difficile Infection.
    Burton HE; Mitchell SA; Watt M
    Pharmacoeconomics; 2017 Nov; 35(11):1123-1140. PubMed ID: 28875314
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New and emerging therapies in treatment of Clostridium difficile infection.
    Goyal H; Perisetti A; Rehman MR; Singla U
    Eur J Gastroenterol Hepatol; 2018 Jun; 30(6):589-597. PubMed ID: 29521664
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in a randomized, double-blind, comparative Phase III study in Japan.
    Mikamo H; Tateda K; Yanagihara K; Kusachi S; Takesue Y; Miki T; Oizumi Y; Gamo K; Hashimoto A; Toyoshima J; Kato K
    J Infect Chemother; 2018 Sep; 24(9):744-752. PubMed ID: 29934056
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An outbreak of Clostridium difficile PCR ribotype 027 in Spain: risk factors for recurrence and a novel treatment strategy.
    Bouza E; Alcalá L; Marín M; Valerio M; Reigadas E; Muñoz P; González-Del Vecchio M; de Egea V
    Eur J Clin Microbiol Infect Dis; 2017 Oct; 36(10):1777-1786. PubMed ID: 28501926
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Update of treatment algorithms for Clostridium difficile infection.
    Ooijevaar RE; van Beurden YH; Terveer EM; Goorhuis A; Bauer MP; Keller JJ; Mulder CJJ; Kuijper EJ
    Clin Microbiol Infect; 2018 May; 24(5):452-462. PubMed ID: 29309934
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic approaches for Clostridium difficile infections.
    Marsh JW; Curry SR
    Curr Protoc Microbiol; 2013 Oct; 30():9A.3.1-9A.3.9. PubMed ID: 24510892
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of outcomes with vancomycin or metronidazole for mild-to-moderate Clostridium difficile associated diarrhea among solid organ transplant recipients: A retrospective cohort study.
    Nguyen CT; Li J; Anders S; Garcia-Diaz J; Staffeld-Coit C; Hand J
    Transpl Infect Dis; 2018 Jun; 20(3):e12867. PubMed ID: 29512244
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of
    Oksi J; Anttila VJ; Mattila E
    Ann Med; 2020; 52(1-2):12-20. PubMed ID: 31801387
    [No Abstract]   [Full Text] [Related]  

  • 34. Management of adult Clostridium difficile digestive contaminations: a literature review.
    Mathias F; Curti C; Montana M; Bornet C; Vanelle P
    Eur J Clin Microbiol Infect Dis; 2019 Feb; 38(2):209-231. PubMed ID: 30498879
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fidaxomicin for the treatment of Clostridium difficile infections.
    Whitman CB; Czosnowski QA
    Ann Pharmacother; 2012 Feb; 46(2):219-28. PubMed ID: 22318930
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fidaxomicin: the newest addition to the armamentarium against Clostridium difficile infections.
    Lancaster JW; Matthews SJ
    Clin Ther; 2012 Jan; 34(1):1-13. PubMed ID: 22284993
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevention of recurrent Clostridioides difficile infection: A systematic review of randomized controlled trials.
    Madoff SE; Urquiaga M; Alonso CD; Kelly CP
    Anaerobe; 2020 Feb; 61():102098. PubMed ID: 31493500
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fidaxomicin (OPT-80) for the treatment of Clostridium difficile infection.
    Miller M
    Expert Opin Pharmacother; 2010 Jun; 11(9):1569-78. PubMed ID: 20446864
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Successful Therapy of Severe Pseudomembranous Clostridium difficile Colitis Using a Combination of Fecal Microbiota Therapy and Fidaxomicin.
    Konturek PC; Haziri D; Helfritzsch H; Hess T; Harsch IA
    Med Princ Pract; 2017; 26(2):182-184. PubMed ID: 27978522
    [TBL] [Abstract][Full Text] [Related]  

  • 40. European Practice for CDI Treatment.
    Fitzpatrick F; Brennan R; van Prehn J; Skally M; Brady M; Burns K; Rooney C; Wilcox MH
    Adv Exp Med Biol; 2024; 1435():57-84. PubMed ID: 38175471
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.